Evidence map›Paper›PMID 32252665›Full record

ArticleBMC cancer2020

The DNA hypermethylation phenotype of colorectal cancer liver metastases resembles that of the primary colorectal cancers.

Stephany Orjuela, Mirco Menigatti, Peter Schraml, Patryk Kambakamba, Mark D Robinson, Giancarlo Marra

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Cell identity and 5-hydroxymethylcytosine.Epigenetics & chromatin · 2025
    Review
  3. Article
  4. Article
  5. Article
  6. Biological factors driving colorectal cancer metastasis.World journal of gastrointestinal oncology · 2024
    Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Stephany OrjuelaInstitute of Molecular Cancer Research, University of Zurich, Winterthurerstrasse 190, 8057, Zurich, Switzerland.
Mirco MenigattiInstitute of Molecular Cancer Research, University of Zurich, Winterthurerstrasse 190, 8057, Zurich, Switzerland.
Peter SchramlDepartment of Pathology and Molecular Pathology, University of Zurich, Zürich, Switzerland.
Patryk KambakambaDivision of Surgical Research, University of Zurich, Zürich, Switzerland.
Mark D RobinsonInstitute of Molecular Life Sciences, University of Zurich and SIB Swiss Institute of Bioinformatics, Zürich, Switzerland.
Giancarlo MarraInstitute of Molecular Cancer Research, University of Zurich, Winterthurerstrasse 190, 8057, Zurich, Switzerland. marra@imcr.uzh.ch.
University of Zurich · CHSIB Swiss Institute of Bioinformatics · CH

Funding

Krebsforschung Schweiz 3397-02-2014Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung 310030-179477
6 · The paper itself

Abstract

backgroundIdentifying molecular differences between primary and metastatic colorectal cancers-now possible with the aid of omics technologies-can improve our understanding of the biological mechanisms of cancer progression and facilitate the discovery of novel treatments for late-stage cancer. We compared the DNA methylomes of primary colorectal cancers (CRCs) and CRC metastases to the liver. Laser microdissection was used to obtain epithelial tissue (10 to 25 × 10

resultsMBD enrichment captured a total of 322,551 genomic regions (249.5 Mb or ~ 7.8% of the human genome), which included over seven million CpG sites. A few of these regions were differentially methylated at an expected false discovery rate (FDR) of 5% in neoplastic tissues (primaries: 0.67%, i.e., 2155 regions containing 279,441 CpG sites; liver metastases: 1%, i.e., 3223 regions containing 312,723 CpG sites) as compared with normal mucosa samples. Most of the differentially methylated regions (DMRs; 94% in primaries; 70% in metastases) were hypermethylated, and almost 80% of these (1882 of 2396) were present in both lesion types. At 5% FDR, no DMRs were detected in liver metastases vs. primary CRC. However, short regions of low-magnitude hypomethylation were frequent in metastases but rare in primaries. Hypermethylated DMRs were far more abundant in sequences classified as intragenic, gene-regulatory, or CpG shelves-shores-island segments, whereas hypomethylated DMRs were equally represented in extragenic (mainly, open-sea) and intragenic (mainly, gene bodies) sequences of the genome. Compared with targeted enrichment, MBD capture provided a better picture of the extension of CRC-associated DNA hypermethylation but was less powerful for identifying hypomethylation.

conclusionsOur findings demonstrate that the hypermethylation phenotype in CRC liver metastases remains similar to that of the primary tumor, whereas CRC-associated DNA hypomethylation probably undergoes further progression after the cancer cells have migrated to the liver.

Indexed as

EpigenomeBiomarkers, TumorColorectal NeoplasmsEpigenesis, GeneticHigh-Throughput Nucleotide SequencingHumansLaser Capture MicrodissectionLiver NeoplasmsPhenotypePromoter Regions, GeneticBiomarkers, TumorColorectal cancerCpG islandsCpG sitesDifferentially methylated regionsDNA methylationLiver metastasisMBD captureMethyl-binding domainNormal colorectal mucosa

Identifiers

PMID32252665
PMCPMC7137338
OpenAlexW3014826241

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.